Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

Creative Commons License

Yumuk P., Turhal N., Gumus M., Hatabay N., Turken O., Ozkan A., ...More

BMC CANCER, vol.5, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2005
  • Doi Number: 10.1186/1471-2407-5-10
  • Journal Name: BMC CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Kütahya Health Sciences University Affiliated: No

Abstract

Background: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lung cancer (NSCLC). The weekly administration of P is active, dose intense, and has a favorable toxicity profile. We retrospectively reviewed the data of 51 consecutive patients receiving C and day 1 and 8 P chemotherapy (CT) regimen in advanced stage NSCLC to evaluate the efficacy and toxicity.